Came across this article on a newswire that I don't recall seeing before.

Resverlogix Corp Applies for Patent on Use of a Compound in the Manufacture of a Medicament for Inhibiting the Expression of IL-6 and/or VCAM-1

 Tue Dec 19 08:40:21 2017 EDT

 Jerusalem, Dec. 18 -- Resverlogix Corp has applied for Israeli patent for use of a compound in the manufacture of a medicament for inhibiting the expression of IL-6 and/or VCAM-1.

 The patent application number is IL20140233822 20140727. The patent publication number is IL233822 (A). International Patent Classification codes are A61K, A61P and C07D. Cooperative Patent Classification codes are A61K31/47, A61K31/5025, A61K31/517, A61K9/4833, C07D215/22, C07D215/36, C07D239/91, C07D239/93, C07D401/02, C07D401/12, C07D403/04, C07D403/12, C07D405/04, C07D413/12 and C07D487/04.

 The abstract of the patent published by the Israeli Patent Office states: "Disclosed are methods of regulating interleukin-6 (IL-6) and/or vascular cell adhesion molecule-1 (VCAM-1) and methods of treating and/or preventing cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s) by administering a naturally occurring or synthetic quinazolone derivative. The invention provides novel synthetic quinazolone compounds, as well as pharmaceutical compositions comprising those compounds."

SID(PEDIA22ba8e57e1f28bd3b7)

--------------------------------------------

Not sure if this is to protect Apabetalone or if it's for another indication.

masila